5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-amine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
halicin : A member of the class of thiadiazoles that is 1,3,4-thiadiazol-2-amine which is substituted by a (5-nitro-1,3-thiazol-2-yl)sulfanediyl group at position 5. It is a c-Jun N-terminal kinase inhibitor (IC50 = 0.7uM) and exhibits antibacterial properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11837140 |
| CHEMBL ID | 510038 |
| CHEBI ID | 146227 |
| SCHEMBL ID | 8044196 |
| MeSH ID | M0535130 |
| Synonym |
|---|
| 2-amino-1,3,4-thiadiazole, 9 |
| bdbm29315 |
| CHEMBL510038 |
| CHEBI:146227 |
| 5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-amine |
| su 3327 , |
| 5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine |
| su3327 |
| 2-amino-5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazole |
| 40045-50-9 |
| 5-[(5-nitro-1,3-thiazol-2-yl)thio]-1,3,4-thiadiazol-2-amine |
| halicin |
| su-3327 |
| AKOS016368573 |
| SCHEMBL8044196 |
| 5-[(5-nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine |
| DTXSID70474254 |
| jnk inhibitor xiii - cas 40045-50-9 |
| HY-107597 |
| HMS3678C07 |
| DB15624 |
| HMS3414C07 |
| su3327; su-3327 |
| BCP32078 |
| CS-0028934 |
| D88541 |
| 5-((5-nitrothiazol-2-yl)thio)-1,3,4-thiadiazol-2-amine |
| A933919 |
| compound 9 [pmid: 19271755] |
| gtpl10703 |
| mfcd01927019 |
| AS-77047 |
| BS175963 |
| unii-y4kqc5p9b2 |
| 1,3,4-thiadiazol-2-amine, 5-((5-nitro-2-thiazolyl)thio)- |
| y4kqc5p9b2 , |
| 5-((5-nitro-2-thiazolyl)thio)-1,3,4-thiadiazol-2-amine |
| 5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazol-2-amine |
| 1,3,4-thiadiazol-2-amine, 5-[(5-nitro-2-thiazolyl)thio]- |
| AKOS040739250 |
| Role | Description |
|---|---|
| c-Jun N-terminal kinase inhibitor | An EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor that inhibits the action of c-Jun N-terminal kinase. |
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| thiadiazoles | |
| 1,3-thiazoles | |
| primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
| C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
| organic sulfide | Compounds having the structure RSR (R =/= H). Such compounds were once called thioethers. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 (µMol) | 10.0000 | 0.0040 | 3.4388 | 9.5100 | AID1640022 |
| Furin | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0180 | 0.0180 | 0.0180 | AID416988 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.0300 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | IC50 (µMol) | 0.5463 | 0.0020 | 1.0173 | 5.4200 | AID1371340; AID1798989; AID1798990 |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | IC50 (µMol) | 0.7000 | 0.0050 | 0.7475 | 5.2000 | AID1371340 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | IC50 (µMol) | 0.7000 | 0.0020 | 1.7035 | 10.0000 | AID1371340 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 0.7266 | 7.8000 | AID416986 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||